Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 13/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17178214 | 0.83 | PDE3B (0.50) | DRD1CNR2PDE3BPDE3A | |
| SCHEMBL19390802 | 0.80 | CNR2 (0.47) | DRD1CNR2TRPA1PDE3BPDE3A | |
| SCHEMBL18903798 | 0.80 | CNR2 (0.47) | DRD1CNR2TRPA1 | |
| SCHEMBL18904007 | 0.78 | CNR2 (0.50) | DRD1CNR2TRPA1PDK1PDK2 | |
| SCHEMBL19371614 | 0.78 | DRD1 (0.64) | DRD1CNR2TRPA1 | |
| SCHEMBL7814847 | 0.74 | TRPA1 (0.50) | DRD1TRPA1 | |
| SCHEMBL18905583 | 0.74 | CNR2 (0.50) | DRD1CNR2TRPA1PDE3BPDE3A | |
| SCHEMBL21626534 | 0.74 | CNR2 (0.50) | DRD1CNR2PDE3BPDE3APDK1 | |
| SCHEMBL17195074 | 0.74 | CNR2 (0.49) | CNR2PDE3BPDE3APDK1HTR2C | |
| SCHEMBL22342520 | 0.71 | CNR2 (0.47) | DRD1CNR2PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180200253-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180200253-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20170165270-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170165270-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-9617275-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617275-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200253-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | COMT, DRD2, NR3C1 | DRD1 5/4885CNR2 418/4885RIPK1 2011/4885 |
| US-20150291625-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | ARRB1, ADRA1D, ADRB1 | DRD1 10/4885CNR2 232/4885RIPK1 1229/4885 |
| US-20170165270-A1 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands | ARRB1, DRD3, ADRB1 | DRD1 10/4885CNR2 183/4885RIPK1 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.